Single nucleotide polymorphism rs3746444 in miR‑499a affects susceptibility to non‑small cell lung carcinoma by regulating the expression of CD200

Ge,Nan; Mao,Chunxia; Yang,Qingbo; Han,Bin; Wang,Yongjie; Xu,Linhao; Yang,Xiuzhi; Jiao,Wenjie; Li,Chuan

doi:10.3892/ijmm.2019.4124

Single nucleotide polymorphism rs3746444 in miR‑499a affects susceptibility to non‑small cell lung carcinoma by regulating the expression of CD200

Authors:
- Nan Ge
- Chunxia Mao
- Qingbo Yang
- Bin Han
- Yongjie Wang
- Linhao Xu
- Xiuzhi Yang
- Wenjie Jiao
- Chuan Li
View Affiliations

Affiliations: Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Hematology, Τhe Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Operation Room, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Published online on: March 5, 2019 https://doi.org/10.3892/ijmm.2019.4124
Pages: 2221-2229

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study evaluated the association between single nucleotide polymorphism (SNP) rs3746444 and the risk of non‑small cell lung carcinoma (NSCLC) in a Chinese population. Computational analyses and luciferase assays were performed to investigate the regulatory relationship between miR‑499a and CD200. In addition, reverse transcription‑quantitative polymerase chain reaction and western blot assays were performed to examine the effect of rs3746444 on the expression of miR‑499a and CD200. The results demonstrated a significant difference in the smoking history of patients carrying malignant pulmonary nodules and those carrying benign pulmonary nodules. Furthermore, CD200 was demonstrated to be a direct target of miR‑499a, and a miR‑499a binding site was located in the 3'UTR of CD200. Notably, the levels of miR‑499a in malignant pulmonary nodules were higher compared with benign pulmonary nodules, while the levels of CD200 were higher in benign pulmonary nodules compared with malignant pulmonary nodules. In addition, the subjects carrying the AA genotype of SNP rs3746444 exhibited upregulated miR‑499a expression and reduced CD200 expression, compared with the subjects carrying AG and GG genotypes. These findings indicate that the SNP rs3746444 in miR‑499a could affect the prognosis of NSCLC patients by regulating the expression of CD200.

View Figures

View References

1	Vilmar AC and Sorensen JB: Customising chemotherapy in advanced nonsmall cell lung cancer: Daily practice and perspectives. Eur Respir Rev. 20:45–52. 2011. View Article : Google Scholar : PubMed/NCBI
2	Barclay AN, Clark MJ and McCaughan GW: Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp. 51:149–157. 1986.PubMed/NCBI
3	Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al: CD200 is a new prognostic factor in multiple myeloma. Blood. 108:4194–4197. 2006. View Article : Google Scholar : PubMed/NCBI
4	Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, et al: Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 171:3034–3046. 2003. View Article : Google Scholar : PubMed/NCBI
5	Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK and Darley RL: CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 21:566–568. 2007. View Article : Google Scholar : PubMed/NCBI
6	Moreaux J, Veyrune JL, Reme T, De Vos J and Klein B: CD200: A putative therapeutic target in cancer. Biochem Biophys Res Commun. 366:117–122. 2008. View Article : Google Scholar
7	Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Zhu J, Markowitz J, Carson WE III, Basu S and Bai XF: A critical role for CD200R signaling in limiting the growth and metastasis of CD200+ melanoma. J Immunol. 197:1489–1497. 2016. View Article : Google Scholar : PubMed/NCBI
8	Karp X and Ambros V: Developmental biology. Encountering microRNAs in cell fate signaling. Science. 310:1288–1289. 2005. View Article : Google Scholar : PubMed/NCBI
9	Weiler J, Hunziker J and Hall J: Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs implicated in human disease? Gene Ther. 13:496–502. 2006. View Article : Google Scholar
10	Latronico MV, Catalucci D and Condorelli G: Emerging role of microRNAs in cardiovascular biology. Circ Res. 101:1225–1236. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chen Y, Fu LL, Wen X, Liu B, Huang J, Wang JH and Wei YQ: Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy. Apoptosis. 19:1177–1189. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sonkoly E, Wei T, Janson PC, Sääf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius A, et al: MicroRNAs: Novel regulators involved in the pathogenesis of psoriasis? PLoS One. 2:e6102007. View Article : Google Scholar : PubMed/NCBI
13	Cheng L, Gao S, Song X, Dong W, Zhou H, Zhao L and Jia L: Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs. Oncotarget. 7:61199–61214. 2016. View Article : Google Scholar : PubMed/NCBI
14	Hansen T, Olsen L, Lindow M, Jakobsen KD, Ullum H, Jonsson E, Andreassen OA, Djurovic S, Melle I, Agartz I, et al: Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One. 2:e8732007. View Article : Google Scholar : PubMed/NCBI
15	Li M, Zhang S, Wu N, Wu L, Wang C and Lin Y: Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3. Sci Rep. 6:231002016. View Article : Google Scholar : PubMed/NCBI
16	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
17	Wang XH, Wang FR, Tang YF, Zou HZ and Zhao YQ: Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. Genet Mol Res. 13:5048–5054. 2014. View Article : Google Scholar : PubMed/NCBI
18	Bohling SD, Davis E, Thompson K, Kussick SJ and Love J: Flow cytometric analysis of CD200 expression by pulmonary small cell carcinoma. Cytometry B Clin Cytom. 90:493–498. 2016. View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
21	Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, Udagawa H, Kirita K, Matsumoto S, Umemura S, et al: CD200-positive cancer associated fibroblasts augment the sensitivity of epidermal growth factor receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors. Sci Rep. 7:466622017. View Article : Google Scholar : PubMed/NCBI
22	Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436. 2008. View Article : Google Scholar : PubMed/NCBI
23	Li L, Pan X, Li Z, Bai P, Jin H, Wang T, Song C, Zhang L and Gao L: Association between polymorphisms in the promoter region of miR-143/145 and risk of colorectal cancer. Hum Immunol. 74:993–997. 2013. View Article : Google Scholar : PubMed/NCBI
24	Saunders MA, Liang H and Li WH: Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA. 104:3300–3305. 2007. View Article : Google Scholar : PubMed/NCBI
25	Xu HY, Wang ZY, Chen JF, Wang TY, Wang LL, Tang LL, Lin XY, Zhang CW and Chen BC: Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. PLoS One. 10:e01220552015. View Article : Google Scholar : PubMed/NCBI
26	Oner T, Yenmis G, Tombulturk K, Cam C, Kucuk OS, Yakicier MC, Dizman D and Sultuybek GK: Association of Pre-miRNA-499 rs3746444 and Pre-miRNA-146a rs2910164 polymorphisms and susceptibility to behcet's disease. Genet Test Mol Biomarkers. 19:424–430. 2015. View Article : Google Scholar : PubMed/NCBI
27	Chen W, Shao D, Gu H, Gong J and Zhang J: Hsa-mir-499 rs3746444 T/C polymorphism is associated with increased risk of coronary artery disease in a Chinese population. Acta Cardiol Sin. 33:34–40. 2017.PubMed/NCBI
28	Toraih EA, Ismail NM, Toraih AA, Hussein MH and Fawzy MS: Precursor miR-499a variant but not miR-196a2 is associated with rheumatoid arthritis susceptibility in an Egyptian population. Mol Diagn Ther. 20:279–295. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zou HZ and Zhao YQ: Positive association between miR-499A>G and hepatocellular carcinoma risk in a Chinese population. Asian Pac J Cancer Prev. 14:1769–1772. 2013. View Article : Google Scholar
30	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
31	Wright GJ, Jones M, Puklavec MJ, Brown MH and Barclay AN: The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology. 102:173–179. 2001. View Article : Google Scholar : PubMed/NCBI
32	Koning N, Swaab DF, Hoek RM and Huitinga I: Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol. 68:159–167. 2009. View Article : Google Scholar : PubMed/NCBI
33	Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH and Sedgwick JD: Regulation of myeloid cell function through the CD200 receptor. J Immunol. 176:191–199. 2006. View Article : Google Scholar
34	Zhang S, Cherwinski H, Sedgwick JD and Phillips JH: Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 173:6786–6793. 2004. View Article : Google Scholar : PubMed/NCBI
35	Minas K and Liversidge J: Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit Rev Immunol. 26:213–230. 2006. View Article : Google Scholar : PubMed/NCBI
36	Olteanu H, Harrington AM, Hari P and Kroft SH: CD200 expression in plasma cell myeloma. Br J Haematol. 153:408–411. 2011. View Article : Google Scholar : PubMed/NCBI
37	Pojero F, Casuccio A, Parrino MF, Cardinale G, Colonna Romano G, Caruso C and Gervasi F: Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of 'normal' residual plasma cell analysis. Cytometry B Clin Cytom. 88:165–182. 2015. View Article : Google Scholar
38	Conticello C, Giuffrida R, Parrinello N, Buccheri S, Adamo L, Sciuto MR, Colarossi C, Aiello E, Chiarenza A, Romano A, et al: CD200 expression in patients with multiple Myeloma: Another piece of the puzzle. Leuk Res. 37:1616–1621. 2013. View Article : Google Scholar : PubMed/NCBI
39	Cannizzo E, Bellio E, Sohani AR, Hasserjian RP, Ferry JA, Dorn ME, Sadowski C, Bucci JJ, Carulli G and Preffer F: Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom. 78:231–238. 2010.PubMed/NCBI
40	Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD and Lorsbach RB: Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 137:93–100. 2012. View Article : Google Scholar
41	Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, et al: New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 117:6267–6276. 2011. View Article : Google Scholar : PubMed/NCBI
42	Kapoor A, Kumar N, Narayan S, Nirban RK, Maharia S, Beniwal SK, Jakhar SL and Kumar HS: 101pda prospective randomized open label phase III study of geftinib versus docetaxel as second or third line therapy in patients with advanced non small cell lung cancer in asian indians. Ann Oncol. 26(Suppl 1): S29–S44. 2015.
43	Siva A, Xin H, Qin F, Oltean D, Bowdish KS and Kretz-Rommel A: Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother. 57:987–996. 2008. View Article : Google Scholar
44	Colmont CS, Benketah A, Reed SH, Hawk NV, Telford WG, Ohyama M, Udey MC, Yee CL, Vogel JC and Patel GK: CD200-expressing human basal cell carcinoma cells initiate tumor growth. Proc Natl Acad Sci USA. 110:1434–1439. 2013. View Article : Google Scholar : PubMed/NCBI
45	Stumpfova M, Ratner D, Desciak EB, Eliezri YD and Owens DM: The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res. 70:2962–2972. 2010. View Article : Google Scholar : PubMed/NCBI